Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by JOHANSSON, C.
Right arrow Articles by MELLSTRÖM, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by JOHANSSON, C.
Right arrow Articles by MELLSTRÖM, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 Oxford University Press

research-article

Bone Density, Bone Markers and Bone Radiological Features in Mastocytosis

CHRISTER JOHANSSON1, GÖSTA ROUPE2, GÖRAN LINDSTEDT3 and DAN MELLSTRÖM1

1Department of Geriatric Medicine, Vasa Hospital S-411 33 Göteborg, Sweden
2Department of Dermatology, Goteborg University Sweden
3Department of Clinical Chemistry, Göteborg University Sweden

We examined the association between severity of disease in mastocytosis and skeletal manifestations and bone markers in 16 patients varying in extent of mastocytosis as determined by the urine excretion of methylimidazoleacetic acid. Both osteoporosis and osteosclerosis were found. Bone density in the hip was significantly higher (p < 0.05) in both men and women with an enhanced histamine metabolite excretion. Patients with only moderately increased mast cell mass had low bone mineral density in the hip, osteoporosis and vertebral fractures. The different skeletal disease patterns in mastocytosis might be the effect on osteoblasts and osteoclasts of biologically active substances. Mast cells release a number of vasoactive substances, including histamine which promotes osteoblasts and heparin and prostaglandin D2 which induce bone resorption by activation of osteoclasts. Systemic mastocytosis is a rare disease characterized by multi-organ infiltration by mast cells and with varying skeletal manifestations including osteoporosis. Treatment with bisphosphonates may be beneficial in arresting osteoporosis in this disorder.

Revision received May 8, 1995.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
L. A. Fitzpatrick, E. Buzas, T. J. Gagne, A. Nagy, C. Horvath, V. Ferencz, A. Mester, B. Kari, M. Ruan, A. Falus, et al.
Targeted deletion of histidine decarboxylase gene in mice increases bone formation and protects against ovariectomy-induced bone loss
PNAS, May 13, 2003; 100(10): 6027 - 6032.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Lotinun, J. D. Sibonga, and R. T. Turner
Triazolopyrimidine (Trapidil), a Platelet-Derived Growth Factor Antagonist, Inhibits Parathyroid Bone Disease in an Animal Model for Chronic Hyperparathyroidism
Endocrinology, May 1, 2003; 144(5): 2000 - 2007.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Tao, K. Flaherty, and A. Bagg
Unusual Hematologic Malignancies: Case 1. Hematologic Malignancy Presenting With Diarrhea and Bony Lesions: Systemic Mastocytosis
J. Clin. Oncol., September 1, 2002; 20(17): 3737 - 3739.
[Full Text] [PDF]

Home page
 NeurologyHome page
R. Thomassen, H. W. van Schaick, and B. A. Blansjaar
Prevalence of dementia over age 100
Neurology, January 1, 1998; 50(1): 283 - 286.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.